Dicerna Pharmaceuticals Inc(DRNA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Current Price

$26.67

RSI

29.799

Beta:

1.048538

February 26, 2021
126M
52.2M
-51.6M

478.475 %
125.140 %
7.774 %
1.289 %

$164,307,000
$23,904,000
$6,176,000
$2,277,000
$295,000
$184,000
587.362 %
287.047 %
171.234 %
671.864 %
60.326 %

$-112,747,000
$-120,459,000
$-88,853,000
$-60,048,000
$-59,513,000
$-62,839,000
6.840 %
-26.238 %
-32.419 %
-0.891 %
5.589 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.